SCHEMBL24470994

SCHEMBL24470994

Cc1oc2ccc(OCc3ccc(F)cc3Cl)cc2c1C(=O)O

nearest known ligand 0.80

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC26A4 O43511 7/20 0.80
POLB P06746 2/20 0.80
KMT2A Q03164 6/20 0.75
MEN1 O00255 5/20 0.75
LMNA P02545 3/20 0.71
HTT P42858 1/20 0.71
BLM P54132 1/20 0.59
ATM Q13315 1/20 0.59
ANO1 Q5XXA6 4/20 0.53
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
MAPT P10636 2/20 0.52
TSHR P16473 1/20 0.52
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24470989 0.89 SLC26A4 (1.00) SLC26A4POLBKMT2AMEN1LMNA
SCHEMBL29712959 0.86 SLC26A4 (1.00) SLC26A4POLBKMT2AMEN1LMNA
SCHEMBL24470996 0.86 SLC26A4 (1.00) SLC26A4POLBKMT2AMEN1LMNA
SCHEMBL24470810 0.83 LMNA (1.00) SLC26A4POLBKMT2AMEN1LMNA
SCHEMBL29712989 0.83 LMNA (1.00) SLC26A4POLBKMT2AMEN1LMNA
SCHEMBL24471003 0.81 SLC26A4 (0.81) SLC26A4POLBKMT2AMEN1LMNA
SCHEMBL29713078 0.81 LMNA (0.78) SLC26A4POLBKMT2AMEN1LMNA
SCHEMBL24470988 0.81 LMNA (0.78) SLC26A4POLBKMT2AMEN1LMNA
SCHEMBL24471023 0.80 TP53 (0.75) SLC26A4POLBKMT2AMEN1LMNA
SCHEMBL24470998 0.80 SLC26A4 (1.00) SLC26A4POLBKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230391739-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2023-12-07 US claimed
EP-4259613-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2023-10-18 EP claimed
WO-2022112345-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO claimed
US-20230391739-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2023-12-07 US disclosed
EP-4259613-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2023-10-18 EP disclosed
CN-116761796-A Aryl derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2023-09-15 CN disclosed
WO-2022112345-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed
WO-2022112345-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391739-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPV3, TRPM6, TRPM4 SLC26A4 382/4885POLB 4670/4885KMT2A 2278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.